Table 1.
Overview of neoantigens in hematological malignancies.
| Hematological malignancy | Source protein of mutated neoantigen | Identification method | References |
|---|---|---|---|
| AML | NPM1 | MS, spontaneous CD8+ T-cell responses | (46, 50, 51) |
| IDH 1 | Spontaneous CD4+ T-cell responses | (44) | |
| IDH 2 | MS | (51) | |
| FLT3 | Spontaneous CD8+ T-cell responses | (38, 43) | |
| PML-RARα, DEK-CAN, ETV6–AML1 | In vitro T-cell recognition | (52–54) | |
| Splice variants: NOTCH2, FLT3, CD44 | Identification of transmembrane proteins | (35, 36) | |
| CLL | ALMS1, C6ORF89, FNDC3B | Spontaneous CD8+ T-cell responses | (17) |
| CML | BCR-ABL | MS, spontaneous CD8+ T-cell responses | (41, 42, 55–59) |
| MCL | Ig heavy/light chain | MS, spontaneous CD4+ T-cell responses | (60) |
| MPN | JAK2 | In vitro T-cell recognition | (48) |
| CALR | In silico prediction, spontaneous CD4+ T-cell responses | (45, 47, 49, 61, 62) | |
| MPL | In silico prediction | (63) | |
| Various | FBXW7 | Spontaneous CD8+ T-cell responses | (45) |
| MYD88 | In silico prediction, in vitro T-cell recognition, spontaneous CD8+ T-cell responses | (40) |
AML, acute myeloid leukemia; ALMS1, Alstrom syndrome protein 1; CALR, calreticulin; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; C6ORF89, chromosome 6 open reading frame 89; FBXW7, F-box/WD repeat-containing protein 7; FLT3, FMS like tyrosine kinase 3; FNDC3B, fibronectin type III domain containing 3B; IDH, isocitrate dehydrogenase; Ig, immunoglobulin; JAK2, janus like kinase 2; MCL, mantle cell lymphoma; MPL, myeloproliferative leukemia virus oncogene; MPN, myeloproliferative neoplasia; MS, mass spectrometry; MYD88, myeloid differentiation primary response protein 88.